Genoptix Announces Participation at the 22nd Annual Roth OC Growth Stock Conference

CARLSBAD, Calif., March 10 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the 22nd Annual Roth OC Growth Stock Conference at the Ritz Carlton in Laguna Niguel, Calif. to be held on March 15-17, 2010.

Tina Nova, Ph.D., president and CEO of Genoptix, will present at the conference on Wednesday, March 17, 2010 beginning at approximately 10:30 a.m. PDT, when she will provide an overview of the Company's specialized diagnostic laboratory services business, growth strategies and financial performance.

The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Genoptix website at www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. An audio replay will be available for 30 days following the initial presentation web cast.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, as well as other forms of cancer. Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market and the S&P SmallCap 600 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Genoptix, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED